CROSSJECT overview

Dijon, France April 2, 2024 – Trading of the stock of Crossject (ISIN: FR0011716265; Euronext: ALCJ) on the Euronext exchange will resume as normal on Wednesday, April 3 at 09:00 CET. Crossject’s press release, entitled “Crossject advances in its U.S. Strategy and reports Financial Results for 2023”, was published at 10:30am CET, due to a delay in receiving certain confirmations. For that reason, Crossject required Euronext to stop trading. Following Euronext’s standard procedure in...

Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDA Expectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE® in Q1 2025 Expectation to complete U.S. New Drug Application (NDA) for ZEPIZURE® in H1 2025 Reinforcement of supply chain [with addition of a second fill-and-finish CDMO] Reporting of a reduced Net loss of €8.5 million versus €11.2 million in 2022 Dijon, France April 2, 2024, 10:30am CET --...

Dijon, France, March 8, 2024 – 7:30 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, today announces its EU Gender Equality Index score reached 96/100 for 2024, marking the third successive year it has been above 90%. The Gender Equality Index is a tool to measure the progress of gender equality in the EU, giving more visibility to areas that need improvement and ultimately supporting policy...